NICE approves treatment for rheumatoid arthritis

NICE has issued a positive final appraisal document recommending upadacitinib, a once-daily oral therapy, for people with previously treated moderate active rheumatoid arthritis (RA). This will expand upadacitinib to the estimated 27,000 people living with RA in England, many for whom current treatment may not be effective.

Upadacitinib, with methotrexate, is recommended as an option for treating adults with moderate RA, where their disease has responded inadequately to intensive therapy with two or more conventional disease-modifying antirheumatic drugs.

read more